Human Recombinant PEDF (from E. coli)

Supplier: PEPROTECH INC.
Ratings: (No Reviews)

Total Ratings: 0
Avg. Ratings: 0.0 out of 5

130-13-5UG 130-13-20UG 130-13-100UG 130-13-250UG 130-13-500UG 130-13-1MG
10772-776EA 132.81 USD
10772-776 10772-778 10772-780 10772-782 10772-784 10772-786
Human Recombinant PEDF (from E. coli)
Proteins and Peptides

PEDF is a noninhibitory serpin with neurotrophic, anti-angiogenic, and anti-tumorigenic properties. It is a 50 kDa glycoprotein produced and secreted in many tissues throughout the body. A major component of the anti-angiogenic action of PEDF is the induction of apoptosis in proliferating endothelial cells. In addition, PEDF is able to inhibit the activity of angiogenic factors, such as VEGF and FGF-2. The neuroprotective effects of PEDF are achieved through suppression of neuronal apoptosis induced by peroxide, glutamate, or other neurotoxins. The recent identification of a lipase-linked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity ( Notari, I. et al. J Biol Chem., Vol. 281, 38022-38037 ) should facilitate further elucidation of the underlying mechanisms of this pluripotent serpin. To date, PEDF-R is the only signaling receptor known to be used by a serpin family member. The unique range of PEDF activities implicate it as a potential therapeutic agent for the treatment of vasculature-related neurodegenerative diseases, such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). PEDF also has the potential to be useful in the treatment of various angiogenesis-related diseases including a number of cancers. Recombinant Human PEDF is a 44.5 kDa non-glycosylated protein containing 400 amino acid residues.


Ordering information: For research use only. Not for use in diagnostic or therapeutic procedures.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR